Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
January 22 2025 - 3:17PM
Edgar (US Regulatory)
Exhibit 1
JOINT FILING AGREEMENT
The
undersigned hereby agree that this Statement on Schedule 13D, dated January 17, 2025 (the “Schedule 13D”), with respect
to the common stock, par value $0.01 per share, of Outlook Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance
with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Joint Filing Agreement (this
“Agreement”) shall be included as an Exhibit to the Schedule 13D. Each of the undersigned agrees to be responsible
for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein.
This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.
IN
WITNESS WHEREOF, the undersigned have executed this Agreement as of the 22nd day of January, 2025.
| Dated: January 22, 2025 |
GMS Ventures and Investments |
| |
|
|
| |
By: |
/s/ Lawrence A. Kenyon |
| |
|
Name: Lawrence A. Kenyon |
| |
|
Title: Attorney-in-Fact |
| |
|
|
| |
Ghiath M. Sukhtian |
| |
|
|
| |
By: |
/s/ Lawrence A. Kenyon |
| |
|
Name: Lawrence A. Kenyon |
| |
|
Title: Attorney-in-Fact |
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Jan 2025 to Feb 2025
Outlook Therapeutics (NASDAQ:OTLK)
Historical Stock Chart
From Feb 2024 to Feb 2025
